Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية للمستحضرات الطبية والزراعية - arab company for medical & agricultural products - ethinylestradiol 50 mcg, levonorgestrel 250 mcg - 50 mcg, 250 mcg

Namibia - English - Namibia Medicines Regulatory Council

pharmacare limited - norgestrel 250 ug,; ethinyl oestradiol 50 ug - tablet - norgestrel 250 ug, ; ethinyl oestradiol 50 ug

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - macrogol 3350 100 g; potassium chloride 1 g; sodium chloride 2 g; sodium sulfate 9 g;  ; macrogol 3350 40 g; potassium chloride 1.2 g; sodium chloride 3.2 g; ascorbic acid 7.54 g;  ; sodium ascorbate 48.11 g;   - powder for oral solution - active: macrogol 3350 100 g potassium chloride 1 g sodium chloride 2 g sodium sulfate 9 g   excipient: citric acid mango flavour va93382 sucralose active: macrogol 3350 40 g potassium chloride 1.2 g sodium chloride 3.2 g excipient: aspartame fruit mix flavour (fruit punch) fv654 va93402 active: ascorbic acid 7.54 g   sodium ascorbate 48.11 g   - for bowel cleansing prior to any procedure requiring a clean bowel.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - linaclotide - capsule - 290microgram

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - mepolizumab - powder for solution for injection - mepolizumab 100 mg - mepolizumab - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patientschronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with corticosteroids and surgery in the last 10 years do not provide adequate disease control.eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (egpa).hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Canada - English - Health Canada

abbvie corporation - linaclotide - capsule - 145mcg - linaclotide 145mcg - miscellaneous gi drugs

Canada - English - Health Canada

abbvie corporation - linaclotide - capsule - 290mcg - linaclotide 290mcg - miscellaneous gi drugs

Canada - English - Health Canada

abbvie corporation - linaclotide - capsule - 72mcg - linaclotide 72mcg - miscellaneous gi drugs

Canada - English - Health Canada

abbvie corporation - upadacitinib - tablet (extended-release) - 15mg - upadacitinib 15mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

abbvie corporation - upadacitinib - tablet (extended-release) - 30mg - upadacitinib 30mg - disease-modifying antirheumatic agents